TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›DSGN›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Design Therapeutics, Inc. (DSGN) financials

Income statement

Design Therapeutics, Inc. (DSGN) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue$226K———$0.00$0.00
Operating income-$8.33M-$35.8M-$67.6M-$78.2M-$62.4M-$79.5M
Operating margin-3685.8%—————
Net income-$8.28M-$35.5M-$63.3M-$66.9M-$49.6M-$69.8M
Net margin-3663.7%—————
EPS (diluted)-$0.52-$0.77-$1.14-$1.19-$0.88-$1.22

Cash flow

Design Therapeutics, Inc. (DSGN) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$8.67M-$29.4M-$51.3M-$58.6M-$43.1M-$54.4M
Capital expenditures$76.0K$1.54M$918K$256K$340K$193K
Free cash flow-$8.74M-$30.9M-$52.2M-$58.8M-$43.4M-$54.6M

Balance sheet

Design Therapeutics, Inc. (DSGN) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$2.38M$299M$26.5M$21.2M$22.6M$16.9M
Total assets$36.5M$391M$341M$290M$252M$226M
Total liabilities$2.48M$8.43M$13.8M$12.0M$10.00M$13.7M
Shareholders' equity-$11.3M$382M$327M$278M$242M$213M
Retained earnings-$11.9M-$47.5M-$111M-$178M-$227M-$297M
Shares (wtd avg diluted)16.0M45.9M55.7M56.0M56.6M57.3M

Every figure is extracted from Design Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Design Therapeutics, Inc.'s annual revenue?
Design Therapeutics, Inc. (DSGN) reported $0.00 of revenue for fiscal year 2025, per its annual report filed with the SEC.
What is Design Therapeutics, Inc.'s free cash flow?
-$54.6M in FY2025 (operating cash flow -$54.4M minus $193K of capital expenditures), from the SEC cash-flow statement.
Does DSGN pay a dividend?
Design Therapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full DSGN analysis — verdict, score & filings →Is DSGN a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.